Mumps

Worldwide Face Mask Industry to 2027 - Focus on Surgical, Respirator, N-Series, R-Series and P-Series - ResearchAndMarkets.com

Retrieved on: 
Monday, January 10, 2022

A face mask is used as a protection against various airborne diseases such as flu, COVID-19, mumps, measles, and chickenpox.

Key Points: 
  • A face mask is used as a protection against various airborne diseases such as flu, COVID-19, mumps, measles, and chickenpox.
  • In the face mask market based on type, the respirators segment dominated the market with the highest share.
  • Thus, the growing prevalence of respiratory diseases has escalated the usage and sales of face masks and higher market value.
  • Moreover, increasing awareness about the benefits of face masks in respiratory diseases is positively impacting the global market size of the face mask.

Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment

Retrieved on: 
Thursday, December 9, 2021

At that time, Sinovacs Board determined that certain collaborating shareholders had become acquiring persons, thereby triggering the Companys Rights Agreement.

Key Points: 
  • At that time, Sinovacs Board determined that certain collaborating shareholders had become acquiring persons, thereby triggering the Companys Rights Agreement.
  • On December 19, 2018, the High Court of Justice of Antigua and Barbuda issued a judgment (the 2018 Judgment) that determined the Companys existing directors were properly elected at the Annual General Meeting (AGM) held in February 2018 and remained as directors of the Company, and that the Companys Rights Agreement is valid under Antigua law.
  • On December 9, 2021, the Eastern Caribbean Supreme Courts Court of Appeal upheld the 2018 Judgment, further confirming SINOVACs position that the board was properly elected, and the Rights Agreement was triggered by a group led by 1Globe Capital, LLC, Chiangjia Li and OrbiMed Advisors LLC.
  • The Court also confirmed the Companys Rights Agreement did not contain any inconsistencies in its Articles or Memorandum of Association, or the Antiguan business law.

SINOVAC Beijing Settled Litigation of Its Business License and Seals

Retrieved on: 
Friday, December 3, 2021

SINOVAC Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced the Companys subsidiary SINOVAC Biotech Co., Ltd (SINOVAC Beijing) settled the litigation with Mr. Aihua Pan concerning its business license and seals.

Key Points: 
  • SINOVAC Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced the Companys subsidiary SINOVAC Biotech Co., Ltd (SINOVAC Beijing) settled the litigation with Mr. Aihua Pan concerning its business license and seals.
  • Mr. Pan subsequently obtained a re-issued business license of SINOVAC Beijing based on the false claim.
  • : 1101081347485), contract seal and invoice seal (collectively, the Seals) by using the re-issued business license.
  • With the settlement, Mr. Pan has returned the business license and the Seals to SINOVAC Beijing, and SINOVAC Beijing has withdrawn its claims with the Court.

Serum Life Sciences invests in RNA biotech GreenLight by joining expanded financing for Environmental Impact Acquisition Corp.

Retrieved on: 
Tuesday, November 23, 2021

The expanded financing includes a $10 million strategic investment from Serum Life Sciences Ltd ("Serum Life Sciences"), a subsidiary of Serum Institute of India Pvt.

Key Points: 
  • The expanded financing includes a $10 million strategic investment from Serum Life Sciences Ltd ("Serum Life Sciences"), a subsidiary of Serum Institute of India Pvt.
  • Natasha Poonawalla, the chairperson of Serum Life Sciences, said: "Serum Life Sciences is delighted to invest in the future of GreenLight Biosciences, with the objective of accelerating the development and distribution of RNA vaccines."
  • Both Serum Life Sciences and GreenLight share a commitment to making healthcare affordable and accessible.
  • "We are delighted to align with Serum Life Sciences through this investment in our future as a public company," said GreenLight CEO Andrey Zarur.

Annals of Family Medicine: Routine Immunization Rates Must Be Recovered to Ensure Long-Term Population Health

Retrieved on: 
Tuesday, November 9, 2021

In a new paper published in the November/December 2021 edition of Annals of Family Medicine , researchersexamine routine vaccination data, give examples of organizations working to prevent disruptions to routine vaccination, and provide strategies for recovering vaccine rates.

Key Points: 
  • In a new paper published in the November/December 2021 edition of Annals of Family Medicine , researchersexamine routine vaccination data, give examples of organizations working to prevent disruptions to routine vaccination, and provide strategies for recovering vaccine rates.
  • "This has dire consequences to future population health and the potential to strain an already overtaxed health system," the authors write.
  • Despite these efforts, the authors argue more needs to be done to get people caught up on routine vaccinations.
  • Innovative models used to administer the COVID-19 vaccinations should also be used to restore routine vaccination rates.

Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population

Retrieved on: 
Tuesday, November 9, 2021

The results from statistics analysis under blind status indicated that CoronaVac is safe for healthy people of different races in the pediatric and adolescent population ranging from 3 to 17 years of age.

Key Points: 
  • The results from statistics analysis under blind status indicated that CoronaVac is safe for healthy people of different races in the pediatric and adolescent population ranging from 3 to 17 years of age.
  • The blind safety data analysis for this subgroup shows a good safety profile among healthy participants aged from 3 to 17 years.
  • The findings suggest that CoronaVac has a good safety profile among the healthy pediatric and adolescent population ranging from 3 to 17 years old.
  • SINOVACs COVID-19 vaccine, CoronaVac, has been granted emergency use approval or conditional marketing authorization by over 50 countries or regions worldwide.

Accesa Labs, symplr Announce Integrated Solution to Streamline and Strengthen the Vendor Credentialing Process

Retrieved on: 
Wednesday, September 29, 2021

Typically, credentialing can be a slow and inefficient process involving phone calls and emails with doctor's offices, paperwork, and uncertain costs.

Key Points: 
  • Typically, credentialing can be a slow and inefficient process involving phone calls and emails with doctor's offices, paperwork, and uncertain costs.
  • Accesa Labs technology automates this process by enabling vendor reps to order tests and services at guaranteed prices from more than 3,000 approved testing locations nationwide.
  • "Vendor credentialing has long played an important role in protecting patients and minimizing business risks for healthcare organizations.
  • Partnering with Accesa Labs accelerates the entire process by quickly green-lighting compliant vendors for access," said Peggy Drew, Sr. Director, Product Management at symplr.

Walmart and Sam’s Club Now Administering Booster Shots

Retrieved on: 
Friday, September 24, 2021

Walmart and Sams Club are now administering Pfizer booster shots in more than 5,100 pharmacies around the country where supply allows.

Key Points: 
  • Walmart and Sams Club are now administering Pfizer booster shots in more than 5,100 pharmacies around the country where supply allows.
  • Walk-In Availability: Walmart and Sams Club have walk-in availability to encourage people to get vaccinated and get their booster shot during their regularly scheduled shopping trips.
  • Walmart also provides COVID-19 testing at select locations, and both Walmart and Sams Club offer over-the-counter medications and low-cost, healthy grocery foods.
  • To learn more about wellness resources available at your neighborhood Walmart, please visit walmart.com/wellnesshub or at Sams Club at samsclub.com .

Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd

Retrieved on: 
Wednesday, September 22, 2021

Oxford, UK 22 September, 2021: Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Group), a leading gene and cell therapy group, today announces that Serum Life Sciences Ltd (SLS), a subsidiary company of Serum Institute of India Pvt Ltd (Serum Institute of India), has agreed to invest just over 50 million in the Group in return for new ordinary shares representing 3.9% of the outstanding shares after the capital increase (the Transaction).

Key Points: 
  • Oxford, UK 22 September, 2021: Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Group), a leading gene and cell therapy group, today announces that Serum Life Sciences Ltd (SLS), a subsidiary company of Serum Institute of India Pvt Ltd (Serum Institute of India), has agreed to invest just over 50 million in the Group in return for new ordinary shares representing 3.9% of the outstanding shares after the capital increase (the Transaction).
  • John Dawson, Chief Executive Officer of Oxford Biomedica, said: We are delighted that Serum Life Sciences Ltd, a subsidiary company of Serum Institute of India, has made this strategic investment into Oxford Biomedica.
  • Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: [email protected]
    Serum Life Sciences Ltd is a subsidiary company of Serum Institute of India Pvt Ltd. Its global sales office in London will market COVID-19 vaccines manufactured by Serum Institute of India Pvt Ltd (SII).
  • Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases.

Austin Doctors Appear in National Video Urging Patients to Get Vaccinated for COVID-19

Retrieved on: 
Monday, September 13, 2021

Now, more than ever, their message is clear: It's time to "Roll Up Our Sleeves" and help stop the spread of COVID-19.

Key Points: 
  • Now, more than ever, their message is clear: It's time to "Roll Up Our Sleeves" and help stop the spread of COVID-19.
  • The goal of the "Roll up Our Sleeves" website and video campaign is to educate those who are still unsure about getting vaccinated.
  • "But experts say that the most trusted messengers for COVID-19 information are healthcare professionals, such as primary care doctors.
  • Their goal is to combat the doubt felt by an alarming percentage of Americans who remain reluctant about getting vaccinated.